1) Strategy & Leadership - Cencora's performance in Q3 2026 was driven by a strong execution of its pharmaceutical-centric strategy, which focuses on specialty pharmaceuticals and digital transformation. - The company emphasized its differentiated specialty pharmaceutical platform that supports innovation and patient care. - Leadership changes include the appointment of Eva Boratto as CFO, who is expected to enhance financial discipline and growth strategies. - The company is committed to investing in talent and culture to equip teams for future growth.

2) Financial & Segment Results - Revenue for Q3 was $84.8 billion, a 5% YoY increase. - Adjusted operating income grew by 17%, reaching $1.2 billion. - Adjusted EPS increased by 12%, leading to a revised fiscal 2026 EPS guidance of $17.75 to $17.95. - The U.S. Healthcare Solutions segment generated $74.9 billion in revenue, also up 5%, with operating income rising 16% to $966 million. - The International Healthcare Solutions segment saw revenue of $7.7 billion, up 6%, with operating income increasing 21%.

3) Problems / Headwinds - The company faced headwinds from manufacturer list price reductions, which impacted revenue growth by approximately $2.4 billion. - The loss of an oncology customer in 2025 and lower sales to a large mail order customer also contributed to challenges in revenue. - Increased net interest expense of $141 million due to debt from the OneOncology acquisition.

4) Operational or Product Plans - Cencora is focused on enhancing its digital transformation, utilizing AI for demand forecasting to improve operational efficiency. - The company is integrating OneOncology and RCA into its operations, with a focus on expanding clinical trial capabilities. - There are ongoing plans for strategic alternatives for certain businesses, with MWI Animal Health showing strong performance. - Cencora is committed to maintaining a robust pipeline for specialty products and exploring tuck-in acquisitions in oncology and retina.

5) Guidance & Outlook / Investor Angle - Cencora raised its fiscal 2026 EPS guidance, reflecting confidence in continued execution and growth. - The company expects U.S. Healthcare Solutions revenue growth to be in the lower half of the 4% to 6% range, while International Healthcare Solutions is projected to grow approximately 8%. - Investors should note the potential impact of regulatory changes, particularly regarding ASP rules and the 340B program, but management remains confident in long-term profitability.

Bottom line: Cencora's strong Q3 results and raised guidance reflect effective execution of its pharmaceutical-centric strategy, positioning the company for sustained growth despite facing some headwinds. The focus on specialty pharmaceuticals and digital transformation enhances its competitive edge, making it a compelling investment for shareholders.